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Abstract
Background: Collaborative medication review (CMR) practices for older adults are evolving in many countries.
Development has been under way in Finland for over a decade, but no inventory of evolved practices has been
conducted. The aim of this study was to identify and describe CMR practices in Finland after 10 years of
developement.
Methods: An inventory of CMR practices was conducted using a snowballing approach and an open call in the
Finnish Medicines Agency’s website in 2015. Data were quantitatively analysed using descriptive statistics and
qualitatively by inductive thematic content analysis. Clyne et al’s medication review typology was applied for
evaluating comprehensiveness of the practices.
Results: In total, 43 practices were identified, of which 22 (51%) were designed for older adults in primary care. The
majority (n = 30, 70%) of the practices were clinical CMRs, with 18 (42%) of them being in routine use. A checklist
with criteria was used in 19 (44%) of the practices to identify patients with polypharmacy (n = 6), falls (n = 5), and
renal dysfunction (n = 5) as the most common criteria for CMR. Patients were involved in 32 (74%) of the practices,
mostly as a source of information via interview (n = 27, 63%). A medication care plan was discussed with the
patient in 17 practices (40%), and it was established systematically as usual care to all or selected patient groups in
11 (26%) of the practices. All or selected patients’ medication lists were reconciled in 15 practices (35%). Nearly half
of the practices (n = 19, 44%) lacked explicit methods for following up effects of medication changes. When
reported, the effects were followed up as a routine control (n = 9, 21%) or in a follow-up appointment (n = 6, 14%).
Conclusions: Different MRs in varying settings were available and in routine use, the majority being comprehensive
CMRs designed for primary outpatient care and for older adults. Even though practices might benefit from national
standardization, flexibility in their customization according to context, medical and patient needs, and available
resources is important.
Keywords: Collaborative medication review, Comprehensive medication review, Concordance and compliance
review, Adherence review, Prescription review, Medicines optimization, Older adults
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Background
Polypharmacy and associated high medication costs com-
monly occur within a small proportion of medicine users,
a majority of which are≥65 years old [1]. As polypharmacy
is associated with increased risk of medication-related
problems, different medicines optimization strategies are
required for various patients [1–3]. According to the Na-
tional Institute of Health and Care Excellence (NICE) in
the United Kingdom (UK), medicines optimization is a
person-centered approach to safe and effective medicines
use to ensure that people obtain the best possible out-
comes from their medicines [2].
Collaborative medication reviews (CMRs) are one of the
methods in medicines optimization to prevent inappropri-
ate medication use and to increase adherence [2, 4–10].
CMR is an internationally recognized term referring to
medication review practices involving pharmacists as re-
viewers of the medication in close collaboration with other
health care professionals. CMR practices differ within coun-
tries and internationally, for example by the context and
the patient groups they are designed for, which healthcare
professionals are involved, the degree of collaboration, and
the degree of patient involvement in the process [5–7, 9,
11–22]. Currently, CMR practices are under development
in many countries, with the most evidence of impact on pa-
tient and service outcomes, for example, the appropriate-
ness of the medication and readmission rates, respectively,
coming from pioneering countries, such as the USA,
Australia, and UK [5–7, 9, 11–21].
Finland has one of the most rapidly aging populations
in the world. As a consequence, resent Government Pro-
grams have focused on finding strategies for managing
risks and costs in geriatric pharmacotherapy in out-
patient and inpatient care [23, 24]. CMRs have been pri-
oritized in the Government Program 2015–2019 for
implementing rational pharmacotherapy as a part of
substantial healthcare reform [25, 26]. Development of
collaborative medication review practices was initiated in
Finland in 2005 as part of a national program aimed to
strengthen community pharmacists’ involvement in pa-
tient care [19, 27]. For that purpose, long-term accredit-
ation training (1.5 years alongside work) for practicing
pharmacists was initiated to attain collaborative compre-
hensive medication review competency [27]. Since then,
CMR practices involving pharmacists and other health
care professionals have evolved in outpatient and in-
patient care [28–31]. Thus, Finland provides an example
of a country with no previous history of patient-oriented
clinical pharmacy practice where initiation of CMRs and
related accreditation training have remarkably fostered
remodeling the pharmacists role in patient care. Sharing
experiences could be helpful in other countries seeking
to evolve pharmacists’ roles in a similar manner. Fur-
thermore, Finland has benchmarked advanced CMR
practices in other countries, particularly in Australia and
USA in the early phase of starting the CMR accreditation
training in 2005 [19, 27]. Despite growing evidence of the
positive outcomes (the appropriateness of the medication
and readmission rates, respectively) associated with CMRs
[5–7, 9, 11–22, 32], there has not been a comprehensive
evaluation of their implementation on a nationwide basis.
Detailed descriptions of CMR procedures performed are
important, as the intensity of their conduct and range of
services provided (for example, prescription reviews vs.
clinical medication reviews) might be associated with vary-
ing productivity, or degree of patient outcomes achieved.
The aim of this study was to identify and describe the state
of CMR practices in Finland after 10 years of development.
Methods
Study design and setting
In seeking to create an inventory to describe the state of
CMR practices in Finland, the researchers conducted a
web-based open call by the Finnish Medicines Agency
(later Fimea) in April–May 2015. The call was targeted
to all health care professionals involved in collaborative
teams reviewing medications of older adults in any
health care context. The inventory was part of Fimea’s
long-term program to promote rational medicine use of
older adults, and the Ministry of Social Affairs and
Health funded a research project on medicines
optimization for older adults (ILMA) [10].
Inventory instrument
The inventory instrument (Additional file 1) was devel-
oped in four phases: 1) drafting the first version of the
instrument; 2) modifying the content of the instrument
with help of the medication review experts; 3) modifying
the instrument to cover all health care contexts; and 4)
pilot testing the instrument.
Phase 1
The first draft of the inventory instrument was adapted
from questions previously used 1) by Fimea to investigate
challenges and solutions in medication management of
older adults [13], 2) by our research group in an inventory
of medication review practices in European Union (EU)
countries [33], and 3) in a systematic review of CMR prac-
tices and their effectiveness in outpatient care [10]. The
questions covering typical phases of a medication review
process were the following (See also Additional file 1): 1)
Where, how and by whom is a patient with medication-
related problems identified? 2) Which health care profes-
sionals are involved in reviewing the medication? 3) How
is the patient involved? 4) How do different health care
professionals and organizations communicate patient in-
formation in different phases of the medication review
process? 5) Where are the patient’s medications reviewed
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(the site/venue and phase of the patient’s care pathway)?
6) How is the actual review of the medications performed?
7) How is the follow-up of implementing medication
changes organized? 8) Is the practice based on any previ-
ous medication review procedure and/or theory? 9) What
kind of tools are used in reviewing medications (electronic
and/or manual)? and 10) What is the context of the prac-
tice? Additionally, the inventory solicited data on the
medication-related issues reviewed, involvement of prox-
ies in the medication review, and treatment follow-up
practices in usual patient care.
Finally, the respondents were asked to indicate the com-
prehensiveness of their practice according to Clyne
et al.(2008) [34], which is a National Health Service
(NHS)-based categorization widely used in the UK and
elsewhere as criteria for standardizing CMRs [13, 22]. It
categorizes CMR practices into the following three cat-
egories: 1) prescription reviews; 2) concordance and com-
pliance reviews; and 3) clinical medication reviews. The
categorization takes into consideration objectives of the
review (addressing technical issues, the patient’s medicines
taking behavior, and the patient’s use of the medicines in
the context of his/her clinical condition), the used patient
information sources, medications reviewed (only prescrip-
tion medicines, both prescription and non-prescription
medicines and other complementary products), and
patient involvement in the review (not involved, usually
involved or always involved). Respondents were asked to
identify the comprehensiveness of their CMR practice by
defining its purpose, i.e., whether it was for: 1) technical
review of prescriptions / list of medications (i.e., prescrip-
tion review); 2) review of the prescriptions, the patient is
involved to discuss medication taking and support adher-
ence (i.e., adherence/concordance review); or 3) review of
the medications in the context of the patient’s clinical
condition (i.e., clinical medication review).
Phase 2
Six medication review experts from different health care
contexts (hospital, community pharmacy and assisted
living) and the Association of Finnish Pharmacies (AFP)
were consulted when forming the final inventory instru-
ment. Questions related to patients and health care pro-
fessionals’ involvement in the medication review process
and in medication-related issues reviewed were modified
according to their feedback. New questions were added
relating to following up implementation of medication
changes and involving proxies in medication reviews.
Phase 3
Questions were rephrased according to experts recommen-
dations to enable to reflect on CMR practices in different
contexts. Some open-ended questions were also changed to
structured questions to reduce response burden.
Phase 4
The inventory instrument was piloted for face and content
validity and technical functionality by the same experts in-
volved in developing it. Changes were minor at this phase,
limited to wording and grammar, not content. The final
inventory instrument is presented in Additional file 1.
Data collection
The inventory was conducted using a snowballing ap-
proach and an open call via the Finnish Medicines
Agency (Fimea’s) website where the invitation letter with
a link to the inventory instrument was openly accessible
in April–May 2015. The link was also widely dissemi-
nated via expert networks and mailing lists. Receivers of
the invitation were encouraged to report as many CMR
practices as they were involved in and to forward the
link to their networks [35]. This data collection method
was chosen, as no previous data or register was available
about the CMR practices and healthcare providers in-
volved in Finland. Two reminders were sent to the same
receivers than the original link 2 weeks after opening the
call (beginning and end of the week). Responding was
voluntary, and respondents did not receive any incen-
tives. Responding to the survey was considered as giving
informed consent.
Data analysis
Data gathered by structured questions were quantita-
tively analyzed for descriptive statistics using frequencies
and percentages by Statistical Package for the Social Sci-
ences (SPSS-21) and Excel-program (2013). Open-ended
questions (indicated in the Additional file 1) were ana-
lyzed qualitatively by inductive thematic content ana-
lysis, meaning that all themes arise directly from the
survey responses [36]. The narrative responses were
read, encoded and categorized into conceptual themes.
The frequencies of appearance of each categorized
theme in the responses were counted, and the results
were presented as frequencies and percentages to obtain
understanding of the medication review process phases
most commonly performed. Incomplete questions were
analyzed as such (information not available).
For the analysis, the reported CMR practices were cat-
egorized into three categories according to their com-
prehensiveness by using Clyne et al’s typology [34]. First,
the respondents were asked to categorize their CMR
practice according to Clyne et al’s typology by selecting
an option from the structured list that best fitted the
purpose of their practice (Additional file 1). To validate
the categorization, the researchers independently per-
formed another categorization by using all the provided
information on the practice, with a special emphasis on
patient information sources, medications, patient in-
volvement and objectives of the review. Active patient
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involvement was required in type 3 practices (clinical medi-
cation review). In Clyne et al., the minimum criteria for ac-
tive patient involvement is that the patient is present [34].
Our interpretation of this criteria is that at minimum the
patient should be interviewed. Finally, the categorization
performed by the researcher was compared with that
performed by the respondent. In cases of discrepancies, the
categorization by the researcher was used.
Results
Medication review practices
In total, 43 CMR practices were identified by 38 respon-
dents, of which 22 (51%) practices were designed for
older people in primary care (Fig. 1). Almost all practices
(n = 42/43) were established after the year 2005. The ma-
jority (n = 30, 70%) of the practices were comprehensive
clinical medication reviews, involving patients in the re-
view process and concentrating on clinical evaluation ra-
ther than reviewing medication lists. Seven (16%) of the
practices were concordance and compliance reviews,
and two (5%) were prescription reviews. It was not pos-
sible to categorize four (9%) of the practices according
to Clyne el al’s typology [34], because they were com-
prised of only one phase of the review process or de-
scribed use of a tool in reviewing medications (for
example, a tool to identify patients with risk factors for
medication-related problems). In 40 out of 43 practices
(93%) the respondent and the researcher agreed on the
categorization of the practice: 3 practices (7%) were
graded by the respondents to be more comprehensive
than did the researchers. The majority of the practices
(n = 29, 67%) were targeted to outpatients, 8 (19%) to in-
patients and 6 (14%) to both types of patients. Fifteen of
the practices (35%) were used in at least two different
health care contexts (Fig. 1). Of the practices, 28 (65%)
were government or municipality funded. Most of the
practices (n = 31, 72%) were established between 2013
and 2015. Eighteen of them (42%), were in routine use,
18 (42%) were in a pilot phase, 4 (9%) under develop-
ment, and one (2%) was in a planning phase.
Identification of patients with medication-related
problems
A checklist with criteria was used in 19 (44%) of the prac-
tices to identify patients with medication-related problems.
Twelve of them included explicit criteria that varied consid-
erably between practices (Table 1). The commonly used
criteria were 1) polypharmacy expressed as number of
medicines in use (n = 6), 2) number of falls (n = 5), and 3)
renal dysfunction (n = 5). Information about the identified
patient with medication-related problems was transmitted
via electronic health records (EHRs) (n = 11, 26%), interper-
sonal communication (n = 7, 16%) or direct contact with
the physician via different communication means, (n = 6,
14%). Most commonly, patients with medication-related
problems were identified by nurses (n = 39, 91%), pharma-
cists (n = 32, 74%) and physicians (n = 28, 65%).
Conducting collaborative medication reviews
CMRs were most commonly conducted at the point of
prescribing (n = 10, 23%), on the ward (n = 10, 23%), or
in assisted living (n = 5, 12%). Nurses (n = 40, 93%) and
physicians (n = 39, 91%) were involved in most of the
practices. Other health care professionals involved were
pharmacists (n = 35, 81%), practical nurses (a title in
Finland for nurses having a 3-year vocational education
that focuses on supportive and technical nursing) (n =
23, 53%), and physiotherapists (n = 6, 14%). In half of
Fig. 1 Health care context of the reported collaborative medication review practices for older adults in 2015 (n = 43, 15 of the practices were
conducted in multiple contexts)
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the practices, pharmacist reviewed medications (n = 22,
51%) (Table 2). Nurses had central contribution
throughout the reviewing process. Most of the responsi-
bilities was shared and conducted collaboratively. Phases
that were acted alone by particular professionals were
most commonly decisions on medication changes by
physicians (n = 17, 40%), follow-up of the medication
changes by practical nurses (n = 8, 19%), and medication
reviews by pharmacists (n = 20, 47%).
CMRs most commonly focused on interactions, medi-
cations without diagnosis, and potentially inappropriate
medications for older adults (PIM’s) (Fig. 2). Few practices
considered appropriateness of the medication according
to national current care guidelines, self-medication and
use of natural products, or patient adherence to the medi-
cations. Electronic National Reference Book and databases
for medicine use in renal dysfunction, for identifying po-
tentially inappropriate medicine use for the aged, interac-
tions and adverse drug reactions, and the clinical decision-
support system for physicians were frequently used to as-
sist in reviewing medications (Fig. 3). Generally, more
than one tool or database was utilized (n = 35, 81%), and
the most common combination was Electronic National
Reference Book and database for medicine use in renal
failure (n = 28, 65%).
Most commonly, the physician decided on medication
changes after hearing other health care professionals
(n = 24, 56%), or decisions were made in a team meeting
(n = 19, 44%). Decisions were seldom made together with
the nurse and the physician (n = 1, 2%), in the ward
(n = 1, 2%), or via remote conferencing (n = 1, 2%).
Information was transferred between healthcare pro-
fessionals or organizations most commonly via patient
information systems (n = 19, 44%), as a written report
(n = 9, 21%), by telephone (n = 7, 16%), through conver-
sation (n = 7, 16%) or electronically (n = 7, 16%). Patients
received information most commonly as a written sum-
mary (n = 16, 37%) or via conversation (n = 15, 35%) with
one or more health care professionals.
Patient involvement
Patients were actively involved in 32 (74%) of the CMR
practices inventoried, mostly as a source of information
via patient interview (n = 27, 63%), but seldom in the im-
plementation of medication changes. A medication care
plan was discussed together with the patient in 17 prac-
tices (40%), and in eight practices (19%) patients updated
the medication list by themselves. A home visit was in-
cluded in 15 practices (35%). Proxies were involved in the
process most commonly as a source of patient informa-
tion (n = 18, 42%), or information was relayed to them
about the patient’s care (n = 7, 16%).
Follow-up
Medication care plans were established routinely as usual
care systematically to all or selected patient groups in 11
of the practices (26%) or to some patients in 11 of the
practices (26%). The medication list was reconciled as
usual and customary care systematically to all or selected
patient groups in 15 of the practices (35%) or to some pa-
tients in four of the practices (9%) routinely. In nearly half
of the practices (n = 19, 44%), information was missing
concerning the ways in which the effects of the medication
changes were followed up. When reported, (n = 24, 56%),
effects were most commonly followed up in a routine
Table 1 Identification criteria for patients with medication-
related problems (includes 12 practices that were reported to
have explicit identification criteria). One checklist consists of
multiple criteria
Identification criteria n % of practices
having criteria
(n = 12)
% of all
practices
(n = 43)
Polypharmacy 6 50 14
8 medicines in use 1 8 2
7 medicines or more 3 25 7
Not defined in detail 3 25 7
Fala 5 42 12
Renal dysfunction 5 42 12
Low GFRb 2 17 5
GFR under 60 1 8 2
GFR under 50 (60) 1 8 2
Not defined in detail 1 8 2
Dizziness 4 33 9
Age 4 33 9
> 75 years 3 25 7
Older person, but age not
explicitly defined
1 8 2
Poor response to treatment 4 33 9
Poor adherence 3 25 7
Acute decline in general condition 3 25 7
Increased need to use health services 2 17 5
Ortostatism 1 8 2
Delirium or disturbance of consciousness 1 8 2
Constipation 1 8 2
Dry mouth 1 8 2
Concerns regarding possible adverse drug
reactions
1 8 2
Unclear or long medication list 1 8 2
Multiple psychotropic medicines in use 1 8 2
Multiple interactions 1 8 2
Liver dysfunction 1 8 2
Living at home 1 8 2
aRespondents did not specify the timeframe of the fall
bGFR glomerulus filtration rate
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control (n = 9, 21%) or in a separate follow-up appoint-
ment (n = 6, 14%). Information about follow-ups was reg-
istered into patient information systems (n = 6, 14%) or
into a care plan (n = 3, 7%).
Discussion
This study was the first inventory of CMR practices in
Finland. The inventory identified a remarkable number
of practices developed within a decade, of which the ma-
jority were comprehensive clinical medication reviews.
Nearly half of the practices were in routine use in vari-
ous healthcare contexts in 2015, which may indicate that
CMRs are becoming a part of usual and customary care.
This inventory provides valuable information for further
optimization of the existing practices and development
of the new ones that were numerous under way in 2015
when the inventory was conducted. The inventory de-
scribes practices and the manner in which they take
place in actual patient care and in more detail than pre-
vious literature [4–9, 37, 38]. Based on the study find-
ings, CMR practice issues requiring more attention and
standardization are: 1) criteria used for identifying older
adults needing medication review, 2) enhancing patient
involvement in implementing the therapeutic plan, par-
ticularly when medication changes are implemented, and
3) enhancing follow-up of medication changes.
Potentially greater proportions of comprehensive CMR
practices reported in Finland compared with other coun-
tries may be due to their origin in such practices as Home
Table 2 Healthcare professionals involved in the collaborative
medication review process (n = 43 practices) and process phases
acted alone by particular professionals (n = 43 practices)
Healthcare professional’s
contribution
Practitioner acting
alone in the phase
of the process
Total number
of practices
(N=43)
PHYSICIAN n % n %
Patient identification 1 2 28 65
Decision making on medication
changes
17 40 17 40
Follow-up of medication changes 1 2 8 19
Patient counseling on medication
changes
2 5 8 19
Medication reconciliation - 2 5
Instructing other health care
professionals on how to
follow-up
1 2 1 2
Patient examination 1 2 1 2
Medication review 1 2 1 2
Charting admission notes
for further review
1 2 1 2
Developing the MR practice - 1 2
PRACTICAL NURSE
Patient identification 3 7 39 91
Patient counseling on medication
changes
5 12 15 35
Follow-up of medication changes 8 19 15 35
Informing other care team
members about the patient’s
health condition
6 14 8 19
Implementation of medication
changes
2 5 8 19
Medication review - 3 7
Patient interview 1 2 2 5
Medication reconciliation 2 5 2 5
Identification of
medication-related problems
1 2 1 2
Ordering additional
patient testing
- 1 2
Developing the MR practice - 1 2
NURSE
Patient identification 6 14 17 40
Follow-up of medication
changes
1 2 5 12
Patient interview - 1 2
Informing other health
care professionals about the
patient’s health condition
- 1 2
Medication review 1 2 1 2
Ordering additional patient
testing
- 1 2
Medication reconciliation - 1 2
Table 2 Healthcare professionals involved in the collaborative
medication review process (n = 43 practices) and process phases
acted alone by particular professionals (n = 43 practices)
(Continued)
Healthcare professional’s
contribution
Practitioner acting
alone in the phase
of the process
Total number
of practices
(N=43)
PHARMACIST
Patient identification 3 7 32 74
Medication review 20 47 22 51
Follow-up of medication
changes
2 5 6 14
Patient interview 5 12 5 12
Developing the practice - 1 2
Patient counseling on
medication changes
- 1 2
PHYSIOTHERAPIST
Evaluation of the patients
ability to function
1 2 1 2
Patient identification - 1 2
Information not available 11 26
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Medicines Reviews (HMRs) in Australia [10, 13, 19, 27].
Benchmarking and cooperating with other countries having
more advanced CMR practices were instrumental for get-
ting started by learning from their experiences. For ex-
ample, the structure of Finland’s CMR process was inspired
from Australia’s HMR program [27]. The HMR process is
initiated by the physician and conducted as a teamwork. In
a home visit the pharmacist reviews the patient’s medica-
tions. The findings are discussed during a collaborative case
conference. The patient is central in the development and
implementation of the medication management plan aim-
ing to maximize the patient’s benefits from the medications
and prevent medication-related problems.
The development of the first Finnish comprehensive
medication review procedures was initiated in 2005 as part
of a long-term continuing education (1.5 years alongside
work) providing accredited medication review competence
for practicing pharmacists [19, 27]. The education revolves
around patient-oriented pharmacotherapy with special
focus on geriatric care, medication review principles and
interprofessional collaboration. In many other countries,
the development of practices has begun from medication
list reviews (i.e. prescription reviews), which have been ex-
tended to more comprehensive procedures [13]. Given
that a wide variety of CMR practices was identified, na-
tional standardization might be considered to ensure
Fig. 2 Medication-related issues to be reviewed in the practices (practices n = 43, several aspects can be reviewed in the same medication review)
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quality in patient care. However, it should be recognized
that different practices are needed in different contexts
with varying resources and patients needs [30, 39].
Compared with CMR practices in other countries,
nurses, particularly practical nurses, seem to have a stron-
ger role in Finland [4–10]. Practical nurses’ contribution
was especially strong in identifying older people needing
medication reviews, but they also contributed commonly
by counseling patients on medication changes and follow-
ing up their implementation. This may be due to the fact
that practical nurses are the health care providers working
most closely with older patients in primary care in
Finland, for example in home care and assisted living. If
they notice any problems with their clients’ medications,
they are expected to report their findings to the nurse,
and when needed, involve the physician in solving the
problems [40]. Our findings indicate that also pharmacists
were quite often involved in identifying patients with
medication-related problems and reviewing their medica-
tions. This has become more common since medication
review accreditation training was started for pharmacists
[41]. Still, the local medication management processes
need to be better coordinated to make better use of the
existing resources [30, 31, 33].
The criteria for identifying older patients with
medication-related problems were missing from the ma-
jority (72%) of the reported practices. Only 12 practices
included the criteria which were commonly 1) the number
of medicines in use, 2) falls and 3) renal dysfunction. In
addition to these, a long and diffuse list of individual cri-
teria, each of them appearing in one of the procedures
was found. This suggests that consensus should be
reached on issues contributing to clinically significant
medication-related problems in older adults. Evidence on
appropriate criteria is still scarce, but it appears that for
example the number of medicines in use is not a priority
Fig. 3 Assisting tools and databases in medication review practices (n = 43), more than one tool and/or database can be used in the same practice
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criterion although widely used [40]. A recent pilot study
suggests that priority criteria should include symptoms
that may be drug-induced such as drowsiness, skin rash or
itch, dizziness and urination problems; having more than
one physician involved in patient care; and more than one
fall in the past 12months [40]. Further research is needed
on the identification criteria to find the older patients
benefitting the most from CMRs.
In this inventory, patients were reported to be involved
in the implementation of the medication changes, not
only serving as a source of background information, in
several practices at different types of the CMRs. It is es-
sential to continue emphasizing and facilitating patient
involvement throughout the medication review process
because involving patients in healthcare decision-making
has found to lead to enhanced adherence and potentially
better treatment outcomes [42]. This empowering trend
has been highlighted in the medicines policy in Finland
and elsewhere in the EU [43, 44].
The reports provided little information about follow-ups
on medication changes. Medication review may have little
effect on patient care if the follow-up is missing or is inad-
equate, or there is no agreement about the implementa-
tion of the medication changes to patient care. Follow-up
of medication changes is an area for improvement in
Finland, but likely for other countries, as well [10].
Limitations
While the inventory was derived from practices in
Finland, lessons learned can be worthy of consideration
by practitioners and policymakers in other countries.
Due to the snowballing approach used, this inventory
does not necessarily cover all CMR practices in Finland
at the time of the inventory. However, there were rich data
received via this method from various CMR practices in
different healthcare settings.
The data reflect evolution of CMR practices by 2015.
Since then, the number and variety of practices have
evolved, possibly in a growing pace because CMRs were
recommended by the Government Program in 2015 for
mitigating health challenges posed by the rapidly aging
population. Further research is recommended to follow
up the most recent developments within the last 4 years.
Future research is also recommended to model interac-
tions within the CMR practices and define outcome vari-
ables and their predictors.
The content validity of the inventory instrument was
carefully examined; however, true construct validity was
not established. Although open-ended questions enabled
the informants to describe practices in their own words,
this might have increased response burden to some in-
formants, thereby influencing accuracy and complete-
ness of their responses.
Practical implications
This first inventory conducted in 2015 of Finnish CMR
practices provides valuable insights for their ongoing de-
velopment. Attention should be paid to selection criteria
for patients, patient involvement, and implementing and
following up medication changes if recommended as a
result of the medication review. Information from this
study can be used beyond Finland for implementing new
CMR practices in other countries. More studies need to
be conducted on patient identification and follow-up to
deepen understanding of these practices.
Conclusions
Different types of CMR practices in varying health care
settings were available and in routine use in Finland in
2015, the majority being designed for primary outpatient
care and for comprehensive reviews of older patients’
medications. Even though practices might benefit from
national standardization, allowing for flexibility in their
customization according to context, medical and pa-
tient needs and available resources is important for
optimizing care.
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